NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments
A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
